Impaired turnover of prolactin receptor contributes to transformation of human breast cells

Cancer Research

Volumn 69, Issue 7, 2009, Pages 3165-3172

  Plotnikov, Alexandr ^a,b   Varghese, Bentley ^a,b   Tran, Thai H ^c   Liu, Chengbao ^c   Rui, Hallgeir ^c   Fuchs, Serge Y ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN RECEPTOR; PROLACTIN;

ARTICLE; BREAST CARCINOGENESIS; BREAST CELL; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; BREAST; BREAST TUMOR; CANCER INVASION; CELL TRANSFORMATION; DOWN REGULATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

BREAST; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; EPITHELIAL CELLS; HUMANS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROLACTIN; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION;

EID: 66149095511     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4033     Document Type: Article

References (45)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Clevenger CV, Fürth PA, Hankinson SE, Schuler LA The role of prolactin in. mammary carcinoma Endocr Rev 2003;24:1-27.
3. Das R, Vonderhaar BK Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 1997; 2:29-39.
4. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004;91: 305-311
5. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997:138: 5555-5560
6. Gill S, Pesten D, Vonderhaar BK, Shousha S. Expres- sion of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 2001;54:956-960
7. Bhatavdekar JM, Patel DD, Shah NG, et al. Prolactin as a local growth promoter in. patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000;26: 540-547
8. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100:2744-2751
9. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K Sandgren EP, Schüler LA. Prolactin induces ERa-positive and ERct-negative mammary cancer in transgenic mice. Oncogene 2003;22:4664-4674
10. Oakes SR, Robertson FG, Kench JG, et al. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 2007;26:543-553
11. Canbay E, Degerli N, Gulluoglu BM, Kaya H1 Sen. M1 Bardakci F. Could prolactin receptor gene polymor- phism play a role in pathogenesis of breast carcinoma? Curr Med Res Opin 2004;20:533-540
12. Bogorad RL, Courtillot C, Mestayer C, et al. Identification, of a galn-of-function mutation of the prolactin receptor in women with benign, breast tumors. Proc Natl Acad Sei U S A 2008;105:14533-14538.
13. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91: 629-634
14. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin, concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64:6814-6819
15. Mujagic Z, Mujagic H. Importance of serum prolactin determination in metastatic breast cancer patients. Croat Med J 2004;45:176-180
16. Frontini L, Lissoni P, Vaghi M, et al. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated meta- static breast cancer. Anticancer Res 2004;24:4223-4226
17. Lissoni P1 Bucovec R, Maluganl F, et al. A clinical, study of taxotere versus taxotere plus the antiprolacti- nemic agent bromocriptine in metastatic breast cancer pretreated with anthracycllnes. Anticancer Res 2002;22: 1131-1134.
18. Lissoni P, Vaghi M, Ardizzoia A, et al. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Neuroendocrlnol Lett 2001;22:27-29
19. Rui H, Kirken RA Farrar WL. Activation of receptor- associated tyrosine kinase JAK2 by prolactin. J Biol Chem 1994;269:5364-5368.
20. Goffin. V, Bernichtein S, Touralne P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005:26: 400-422.
21. Fun G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem 1995;270:13133-13137
22. Li Y, Kumar KG, Tang W, Spiegelman VS, Fuchs SY. Negative regulation, of prolactin, receptor stability and signaling mediated by SCF(fi-TrCP) E3 ubiquitin ligase. Mol Cell Biol 2004;24:4038-4048
23. Swaminathan G, Varghese B, Fuchs SY. Regulation of prolactin receptor levels and activity in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:81-91.
24. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression, of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 1995:146: 695-705.
25. Li Y, Clevenger CV Minkovsky N, et al. Stabilization of prolactin receptor in breast cancer cells. Oncogene 2006;25:1896-1902.
26. Plotnikov A, Li Y, Tran TH, et al. Oncogene-mediated inhibition, of glycogen, synthase kinase 3ß impairs degradation of prolactin receptor. Cancer Res 2008;68: 1354-1361
27. Levesque AA, Kohn EA1 Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-OI-mediated abrogation of DNA dam- age-induced arrest at S and G2 cell cycle checkpoints. Oncogene 2005;24:3786-3796
28. Varghese B, Barriere H, Carbone CJ, et al. Polyubi- quitination of prolactin receptor stimulates its internal- ization, postinternalizatlon sorting, and degradation, via the lysosomal pathway. MoI Cell Biol 2008;28:5275-5287
29. Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, Fuchs SY. Targeting ß-transducin. repeat-containing protein E3 ubiquitin ligase augments the effects of anti- tumor drugs on breast cancer cells. Cancer Res 2005;65:1904-1908.
30. Fang F, Antico G, Zheng J, Clevenger CV. Quantifi- cation, of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol 2008:8:11.
31. Spiegelman VS, Tang W, Chan AM, et al. Induction, of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J Biol Chem 2002;277:36624-36630
32. Doble BW, WoodgettJR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sei 2003;116:1175-1186
33. Swaminathan G, Varghese B, Thangavel C, et al. Prolactin stimulates ubiquitination, initial internalization and degradation of its receptor via catalytic activation of Janus kinase 2. J Endocrinol 2008;196:Rl-7.
34. Schroeder MD, Symowicz J, Schüler LA. PRL modulates cell cycle regulators in mammary tumor epithelial cells. MoI Endocrinol 2002;16:45-57
35. Clevenger CV, Kline JB. Prolactin receptor signal transduction. Lupus 2001;10:706-718.
36. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F, From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia 2008:13: 147-56.
37. Nabeshima K Inoue T, Shimao Y, Sameshima T. Matrix, metalloproteinases in. tumor invasion: role for cell migration. Pathol Int 2002;52:255-264
38. De Petrocellis L, Melck D, Palmisano A et al. The endogenous can.nabi.noid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sei U S A 1998;95:8375-8380.
39. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V. Involvement of the cAMP/ protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999;463:235-240
40. Melck D, De Petrocellls L, Orlando P, et al. Suppression of nerve growth factor TVk receptors and prolactin receptors by endocannabinoids leads to Inhibition of human breast and prostate cancer cell proliferation Endocrinology 2000;141:118-126
41. Di Marzo V Melck D, De Petrocellis L, Bisogno T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Médiat 2000; 61:43-61.
42. Nevalainen MT, Xie J, Torhorst J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004;22:2053-2060
43. Yamashita H, Nishio M, Ando Y, et al. StatS expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2006;13:885-893
44. Cotaria I, Ren S, Zhang Y, Gehan E, Singh B, Fürth PA Stat5a is tyrosine phosphoryiated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004;108:665-671
45. Utama FE, LeBaron MJ, Neilson LM, et al. Human prolactin receptors are insensitive to mouse prolactin: Implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 2006;188:589-601.